Assessment of LBR-101 In Chronic Migraine

The requested reference [3c1707d671559dfddf9ed71be64c13312435c3fc] no longer exists in our database. It has been replaced by the current reference: [fde269c4f9d23309a7c8661b20db7ff5e6fcaa80]

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
The purpose of the study is to determine whether monthly subcutaneous administration of LBR-101 (fremanezumab) is safe and provides migraine prevention in patients with chronic migraine.
Epistemonikos ID: d9fd848dd2736f9f96bd3d84872adedc1e5448ff
First added on: May 11, 2024